There are 3161 resources available
LBA76 - Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC): A randomized, open-label, phase III study (ETER100)
Presenter: Xinan Sheng
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA24 - Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2
Presenter: Myriam Chalabi
Session: Proffered paper session 1: GI tumours, lower
Resources:
Abstract
Slides
Webcast
CN66 - Healthcare needs, experiences of cancer care, and attitudes towards cancer among ethnic Chinese immigrants in Scotland
Presenter: Lin Cheng
Session: Cancer patients and advocacy
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Next generation of combinations in early clinical trials
Resources:
Webcast
Q&A and discussion
Session: Cancer patients and advocacy
Resources:
Webcast
813MO - Phase I trial of a personalized multi-peptide vaccine combined with the TLR1/2 ligand XS15 under Bruton-Tyrosine-Kinase inhibitor (BTKi) treatment in chronic lymphocytic leukemia (CLL) patients
Presenter: Christopher Hackenbruch
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
Webcast
713MO - Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial
Presenter: Oliver Klein
Session: Mini oral session 1: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
449MO - Macrophage derived immunotherapy in glioblastoma: Phase I TEM-GBM-001 results
Presenter: Fabio Ciceri
Session: Mini oral session: CNS tumours
Resources:
Abstract
Webcast
344MO - ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases
Presenter: Fei Ma
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA77 - Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial
Presenter: Chiara Ciccarese
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast